首页PTKFF • OTCMKTS
add
卡尔贝制药公司
市场资讯
财务信息
损益表
收入
净收入
| (IDR) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | 7.91万亿 | 7.16% |
经营支出 | 2.29万亿 | 15.55% |
净收入 | 5732.83亿 | 6.97% |
净利润率 | 7.25 | -0.14% |
每股收益 | 12.41 | 7.73% |
息税折旧摊销前利润 | 8748.12亿 | 1.14% |
有效税率 | 23.01% | — |
资产负债表
总资产
负债总额
| (IDR) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 4.32万亿 | 45.45% |
总资产 | 28.75万亿 | 5.78% |
负债总额 | 4.84万亿 | 0.67% |
权益总额 | 23.91万亿 | — |
发行在外的股份 | 461.49亿 | — |
市净率 | 0.00 | — |
资产回报率 | 6.15% | — |
资本回报率 | 7.16% | — |
现金流
现金净变动
| (IDR) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | 5732.83亿 | 6.97% |
来自运营的现金 | 1.16万亿 | 22.56% |
投资现金 | -1766.41亿 | 33.78% |
融资现金 | -4211.08亿 | 51.91% |
现金净变动 | 4818.57亿 | 1,978.42% |
自由现金流 | 7520.02亿 | 13.84% |
简介
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. Wikipedia
成立时间
1966年9月10日
员工数量
12,924
